Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

Table 2

Five pivotal trials for adjuvant trastuzumab in breast cancer.

Study	Control arm	Trastuzumab arm	Reduction in relative risk of recurrence	DFS hazard ratio
NSABP B-31 ()	AC → T	AC → TH	Joint analysis; 52%	0.48
NCCTG N9831 ()	AC → T	AC → TH
HERA ()	Any	Trastuzumab 1 year	46%	0.54
BCIRG 006 ()	AC → D	AC → DH; DCH	40%; 33%	0.49; 0.61
FINHer ()	D → FEC; V → FEC	DH → FEC; VH → FEC		0.42

NSABP, National Surgical Adjuvant Breast and Bowel Project; NCCTG, North Central Cancer Treatment Group; HERA, Herceptin Adjuvant Trial; BCIRG, Breast Cancer International Research Group; FINHer, Finland Herceptin Study. A, doxorubicin; C, cyclophosphamide; D, docetaxel; E, epirubicin; F, fluorouracil; H, trastuzumab; T, paclitaxel; V, vinorelbine; DFS, disease-free survival.